{"id":276,"date":"2023-04-29T23:04:10","date_gmt":"2023-04-30T04:04:10","guid":{"rendered":"https:\/\/coco66.com\/new-diabetes-drug-shows-promise-for-weight-loss-in-obese-individuals\/"},"modified":"2023-04-29T23:04:10","modified_gmt":"2023-04-30T04:04:10","slug":"new-diabetes-drug-shows-promise-for-weight-loss-in-obese-individuals","status":"publish","type":"post","link":"https:\/\/coco66.com\/new-diabetes-drug-shows-promise-for-weight-loss-in-obese-individuals\/","title":{"rendered":"New Diabetes Drug Shows Promise for Weight Loss in Obese Individuals"},"content":{"rendered":"

A new drug called tirzepatide, which is currently used to treat Type 2 diabetes, has shown promising results in aiding weight loss in obese and overweight individuals with diabetes.[0]<\/a><\/sup> Eli Lilly, the manufacturer of the drug, reported that in a late-stage trial involving over 900 participants, tirzepatide helped people lose up to 16% of their starting weight over roughly 17 months, an average of 34 pounds. More than 80% of people taking tirzepatide lost at least 5% of their body weight compared to about 30% of those taking a placebo. In a previous phase 3 study conducted this year, Lilly demonstrated that individuals who were overweight or obese, but did not have diabetes, experienced a reduction in up to 22.5% of their body weight while being administered tirzepatide. <\/p>\n

Tirzepatide is part of a family of medications called GLP-1 agonists, which mimic a hormone released when we eat food.[1]<\/a><\/sup> In addition to boosting insulin production, they curtail liver's sugar production, suppress hunger, and decelerate the digestive system.[2]<\/a><\/sup> Two other GLP-1 agonists, Ozempic and Wegovy, from Novo Nordisk, are also in high demand in the US because of their weight loss effects.[1]<\/a><\/sup> <\/p>\n

The trial evaluated 938 adult participants with obesity and type 2 diabetes, who received a weekly injection of tirzepatide or a placebo for 72 weeks, with two doses of tirzepatide studied: a 10-milligram dose and a 15 mg dose.[1]<\/a><\/sup> All participants in the tirzepatide treatment arms started the study at a dose of tirzepatide 2.5 mg once-weekly and then increased the dose in a stepwise approach at four-week intervals to their final randomized maintenance dose of 10 mg or 15 mg.[3]<\/a><\/sup> The results showed that those taking the highest dose achieved weight reductions of 15.7% on average of their body weight, losing up to 34.4 lbs (15.6 kg); while those taking 10 mg dose lost up to 13.4%, or 29.8 lbs (13.5 kg).[4]<\/a><\/sup><\/p>\n

The drug, tirzepatide, is being submitted for FDA approval as a weight loss medication, and Eli Lilly expects an update to the process in late 2023, according to a press release.[5]<\/a><\/sup><\/p>\n

0. <\/span>“People with diabetes lost up to 34 pounds taking Eli Lilly drug, company says” KPRC Click2Houston, 28 Apr. 2023, https:\/\/www.click2houston.com\/news\/local\/2023\/04\/28\/people-with-diabetes-lost-up-to-34-pounds-taking-eli-lilly-drug-company-says<\/a><\/p>\n

1. <\/span>“People with diabetes lost up to 34 pounds taking Eli Lilly drug, company says” NBC News, 27 Apr. 2023, https:\/\/www.nbcnews.com\/health\/health-news\/people-diabetes-lost-34-pounds-taking-eli-lilly-drug-company-says-rcna81577<\/a><\/p>\n

2. <\/span>“Weight loss drugs: Semaglutide, tirzepatide, liraglutide compared” Insider, 28 Apr. 2023, https:\/\/www.insider.com\/different-weight-loss-drugs-types-ozempic-mounjaro-wegovy-saxenda-2023-4<\/a><\/p>\n

3. <\/span>“Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in …” PR Newswire, 27 Apr. 2023, https:\/\/www.prnewswire.com\/news-releases\/lillys-tirzepatide-achieved-up-to-15-7-weight-loss-in-adults-with-obesity-or-overweight-and-type-2-diabetes-in-surmount-2–301809033.html<\/a><\/p>\n

4. <\/span>“Trial Results Position Mounjaro for Weight Loss Drug Approval” diaTribe Foundation, 28 Apr. 2023, https:\/\/diatribe.org\/new-lilly-trial-results-show-big-weight-loss-results-positioning-mounjaro-obesity-drug-approval<\/a><\/p>\n

5. <\/span>“Eli Lilly releases more data for new obesity drug, moving toward fast-track approval” MPR News, 27 Apr. 2023, https:\/\/www.mprnews.org\/story\/2023\/04\/27\/npr-eli-lilly-releases-more-data-for-new-obesity-drug-moving-toward-fast-track-appro<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

A new drug called tirzepatide, which is currently used to treat Type 2 diabetes, has shown promising results in aiding weight loss in obese and overweight individuals with diabetes.[0] Eli Lilly, the manufacturer of the drug, reported that in a late-stage trial involving over 900 participants, tirzepatide helped people lose up to 16% of their […]<\/p>\n","protected":false},"author":2,"featured_media":275,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"_links":{"self":[{"href":"https:\/\/coco66.com\/wp-json\/wp\/v2\/posts\/276"}],"collection":[{"href":"https:\/\/coco66.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/coco66.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/coco66.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/coco66.com\/wp-json\/wp\/v2\/comments?post=276"}],"version-history":[{"count":1,"href":"https:\/\/coco66.com\/wp-json\/wp\/v2\/posts\/276\/revisions"}],"predecessor-version":[{"id":277,"href":"https:\/\/coco66.com\/wp-json\/wp\/v2\/posts\/276\/revisions\/277"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/coco66.com\/wp-json\/wp\/v2\/media\/275"}],"wp:attachment":[{"href":"https:\/\/coco66.com\/wp-json\/wp\/v2\/media?parent=276"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/coco66.com\/wp-json\/wp\/v2\/categories?post=276"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/coco66.com\/wp-json\/wp\/v2\/tags?post=276"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}